MIM
KRYS icon

MetLife Investment Management’s Krystal Biotech KRYS Stock Holding History

MetLife Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.5M Sell
13,542
-302
-2% -$80.4K 0.02% 780
2025
Q4 		$3.41M Sell
13,844
-586
-4% -$123K 0.02% 803
2025
Q3 		$2.55M Sell
14,430
-316
-2% -$47.3K 0.01% 974
2025
Q2 		$2.03M Buy
14,746
+222
+2% +$32.6K 0.01% 981
2025
Q1 		$2.62M Sell
14,524
-473
-3% -$79.6K 0.01% 913
2024
Q4 		$2.35M Buy
14,997
+680
+5% +$121K 0.01% 959
2024
Q3 		$2.61M Hold
14,317
– – 0.01% 887
2024
Q2 		$2.63M Buy
14,317
+3,213
+29% +$539K 0.02% 850
2024
Q1 		$1.98M Sell
11,104
-267
-2% -$37.1K 0.01% 956
2023
Q4 		$1.41M Hold
11,371
– – 0.01% 1126
2023
Q3 		$1.32M Hold
11,371
– – 0.01% 1093
2023
Q2 		$1.33M Buy
11,371
+190
+2% +$19.4K 0.01% 1114
2023
Q1 		$895K Hold
11,181
– – 0.01% 1268
2022
Q4 		$886K Hold
11,181
– – 0.01% 1280
2022
Q3 		$779K Buy
11,181
+915
+9% +$66.1K 0.01% 1318
2022
Q2 		$674K Hold
10,266
– – 0.01% 1455
2022
Q1 		$683K Buy
10,266
+3,618
+54% +$226K ﹤0.01% 1584
2021
Q4 		$465K Hold
6,648
– – ﹤0.01% 1546
2021
Q3 		$347K Hold
6,648
– – ﹤0.01% 1741
2021
Q2 		$452K Buy
6,648
+1,015
+18% +$70.8K ﹤0.01% 1628
2021
Q1 		$434K Hold
5,633
– – ﹤0.01% 1610
2020
Q4 		$338K Hold
5,633
– – ﹤0.01% 1693
2020
Q3 		$243K Hold
5,633
– – ﹤0.01% 1744
2020
Q2 		$233K Buy
5,633
+1,124
+25% +$54.1K ﹤0.01% 1809
2020
Q1 		$195K Hold
4,509
– – ﹤0.01% 1710
2019
Q4 		$250K Hold
4,509
– – ﹤0.01% 1852
2019
Q3 		$157K Hold
4,509
– – ﹤0.01% 2076
2019
Q2 		$182K Buy
+4,509
New +$147K ﹤0.01% 2084

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's KRYS Position: Q1 2026 in Review

MetLife Investment Management reduced its Krystal Biotech (KRYS) stake by 2.2% in Q1 2026, selling an estimated $80.4K and leaving 13,542 shares worth $3.5M. The position accounts for 0.02% of the portfolio, ranked #780.

MetLife Investment Management first reported a position in KRYS in Q2 2019 and has held it in 28 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • MetLife Investment Management held 13,542 shares of Krystal Biotech worth $3.5M as of Q1 2026.
  • MetLife Investment Management sold 302 Krystal Biotech shares in Q1 2026, an estimated $80.4K.
  • Krystal Biotech made up 0.02% of MetLife Investment Management's portfolio in Q1 2026, its #780 holding.
  • MetLife Investment Management first reported a position in Krystal Biotech in Q2 2019 and has held it in 28 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.